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ABSTRACTS1390: ASSESSING THE VALIDITY OF THE PCPT AND ERSPC RISK CALCU-
LATORS FOR PROSTATE CANCER IN A COHORT OF THE POPULATION AT
HIGHEST RISK OF PROSTATE CANCER IN EUROPE
Dara Lundon 1, Brian Kelly 3, William Watson 4, John Fitzpatrick 2,
David Quinlan 1, Killian Walsh 3, David Galvin 1. 1 St.Vincents University
Hospital, Dublin, Ireland; 2Mater Misericordiae University Hospital, Dublin,
Ireland; 3University Hospital Galway, Galway, Ireland; 4Conway Institute of
Biomedical and Biomolecular Research, University College Dublin, Dublin,
Ireland.
Introduction: Prostate Cancer is the most common non-cutaneous ma-
lignancy amongst men in developed nations. Prostate biopsy(TRUS-PBx)
carries with it signiﬁcant risks. Tools exist which assess the possible
outcome of TRUS-PBx before exposing a patient to these risks. Our
objective was to assess the predictive accuracy of the Prostate Cancer
Prevention Trial Prostate Cancer Risk Calculator(PCPT-PCRC) and the Eu-
ropean Randomized Study of Screening for Prostate Cancer Risk Calculator
(ERSPC-RC) in a cohort from Ireland.
Methods: We prospectively collected relevant information on all men
undergoing a TRUS prostate biopsy. Prostate cancer diagnosis risk and high
grade disease risk were correlated with the ﬁnal biopsy histological grade,
and novel analytical techniques were utilised to assess clinical utility of
these tools.
Results: Of 800 prostate biopsies, cancer was subsequently diagnosed in
392 (49%). Of these cancer diagnoses, 192 (24 %) had high grade disease.
Correlation between Risk & PCPT-RC ERSPC-RC. Cancer diagnosis <0.05
<0.05. High Grade Disease Dx <0.05 <0.05
Conclusions: The PCPT-RC and the ERSPC-RC both demonstrate statisti-
cally signiﬁcant prediction of both prostate cancer and high grade disease
diagnoses in an Irish Cohort. Both models can be used accurately in this
cohort. However following assessment the PCPT-RC demonstrates greater
clinical utility in this cohort.
1408: SHOULD ACUTE PYELONEPHRITIS BE MANAGED UNDER
UROLOGISTS?
Rachel Darnell, Michael Shenouda, Lucy Freeman, Eleanor Winstanley,
Miranda Lewis, Olatundun Macaulay, William Dunsmuir. St Peter's
Hospital, Chertsey, UK.
Aims: Pyelonephritis is traditionally managed under the care of physi-
cians; however, in our institution it is managed primarily under urologists.
We sought to assess the proportion of patients admitted with acute py-
elonephritis requiring surgical intervention.
Methods: Prospective audit of all patients admitted with pyelonephritis or
systemic infection of urinary tract origin over 7 weeks at a DGH. Data
collected included demographics, laboratory and radiological in-
vestigations, and surgical intervention.
Results: 31 consecutive patients, with mean age 52 years (range 17-95),
and F:M ratio of 2.6:1. 42% patients had an entirely normal urinary tract
USS. 10 patients (32%) had evidence of hydronephrosis or an obstructed
system on USS or CT, of which 5 had associated impairment of renal
function. 7 patients (23%) required urgent invasive intervention (surgery,
nephrostomy), all of whom had abnormal imaging and raised inﬂamma-
tory markers; 4 also had deranged renal function. Average time to surgical
intervention, from decision to operate, was 9.6 hours.
Conclusion: Acute pyelonephritis and severe urinary sepsis can have
potentially serious complications, and may often require urgent invasive
intervention. We recommend early urological input to facilitate adequate
and timely surgical intervention where necessary. This should ensure
optimal patient care and prevention of avoidable delays to treatment.
1417: TO ASSESS THE DIFFERENCES IN ONCOLOGICAL OUTCOMES OF PA-
TIENTS WITH PT0 STAGE AFTER RADICAL CYSTECTOMY (RC) FOR URO-
THELIAL CARCINOMA OF URINARY BLADDER WITH AND WITHOUT
NEOADJUVANT CHEMOTHERAPY THERAPY (NAT)
Vijay Rao Gudla, G.M. Nandwani, N. Shaikh, N. Ragavan, S.K. Addla.
Bradford Teaching Hospital, Bradford, UK.
Introduction: NAT with RC is the standard of care for muscle invasive
bladder tumour. It has been seen that patients with high stage have better
outcomes with NAT. Oncological outcomes with and without NAT are not
well known for patients with pT0. To throw more light on this subject we
conducted a study on patients with pT0 disease.Methods:Studycohort includedpatients fromJan2006 toSept2012whohad
pT0N0M0 stage after RC and thesewere divided into 2 groups on the basis of
NAT. Progression free survival (PFS), overall survival (OS)were calculated and
complications were recorded according to Clavian grading system.
Results: There were 30 patients in the study, 14 had NAT. Median age,
hospital stay and follow-up were 64 years, 13 days and 31 months
respectively. Complications occurred in 8 (26.6%), majority being grade 1 &
2 (16.6%). Higher rate of complications occurred in NAT group (35.7%) in
comparison to non NAT group (18.75%). There were no deaths in either
group. PFS were 92.85% and 93.75% in NAT group and non NAT group.
Conclusions: Morbidity and mortality of RC with and without neo adju-
vant therapy was acceptable and OS and PFS were not different.VASCULAR / ENDOVASCULAR SURGERY
0052: A STUDY OF SMOKING CESSATION IN VASCULAR PATIENTS: ARE
WE DOING ENOUGH AND DOES IT MATTER?
G. Estebanez, D. Hunt, P. Wilson, C. Humphrys, S. Dimitri. Countess of
Chester Hospital, Chester, UK.
Purpose: Smoking is the leading risk factor for vascular disease, and
therefore smoking cessation strategies are paramount in prevention and
treatment of vascular disease. Our aim was to determine if smoking
cessation advice and treatment was provided to all smoking vascular ad-
missions, and its effectiveness.
Method: A telephone survey was performed for all vascular admissions,
within a twelve month period, to ascertain if they were a smoker, if they
received smoking cessation advice/treatment, their openness to this, and
whether they subsequently quit smoking.
Results: Of the 310 admissions, 187 were available for interview. Of these,
50 (27%) were smokers and 137 (73%) were not. 26 (52%) of the smokers
were given smoking cessation advice, and 24 of these were open to this
advice, however only 6 (23%) were started on treatment. 7 (27%) of those
given advice quit smoking, including 4 of the 6 given treatment. In com-
parison, only 3 of the 24 (12%) patients who did not receive advice/treat-
ment actually quit.
Conclusion: Smoking cessation advice and treatment is a simple but
effective means of improving prognosis and readmission rates. However,
its provision is inadequate and ore aggressive strategies are needed.
0058: RISK OF UNDERLYING MALIGNANCY IN PATIENTS AGED 60 OR
OVER WITH IDIOPATHIC VENOUS THROMBO-EMBOLISM MAY BE
MUCH HIGHER THAN CURRENT DATA SUGGESTS
Veejay Bagga, Gary Lambert, Stanley Silverman. Sandwell West Birmingham
Hospitals NHS Trust, City Hospital, Birmingham, UK.
Introduction: We investigated the risk of underlying malignancy in pa-
tients presenting with idiopathic venous thromboembolism (VTE).
Methods: A retrospective case control study into presentations of VTE to a
single NHS Trust between 2005-2008 was conducted. All diagnoses of VTE
were analysed, identifying cases of idiopathic VTE. Cases were compared to
the regional cancer registry, identifying those subsequently diagnosed
with malignancy after diagnosis of idiopathic VTE. Controls were age-sex
matched from patients presenting with symptoms of VTE but negative
duplex scan or venogram.
Results: 225 patients presented idiopathic VTE between 1st January 2005
and 31st December 2008. 16 (7.1%) were later diagnosed with malignancy,
compared with 5 (2.2%) in controls (Odds ratio 3.36, P¼<0.05). Of those in
the VTE group aged 60 or over, 15 of 112 (13.4%) subsequently developed
cancer vs 5 controls (OR 3, p<0.5). Mean case time to malignant diagnosis
was 255 days.
Conclusions: Patients aged 60 or over presenting with idiopathic VTE have
signiﬁcantly higher risk of underlying malignancy than previously re-
ported and should therefore undergo further detailed screening to look for
occult malignancy.
0059: FAST-TRACK PATHWAYS IN THE MANAGEMENT OF DEEP VENOUS
THROMBOSIS: MISSED OPPORTUNITIES IN CANCER DIAGNOSIS
Gary Lambert, Veejay Bagga, Stanley Silverman. Sandwell West Birmingham
Hospitals NHS Trust, City Hospital, Birmingham, UK.
